Physician profile
Mohammad Ali
NPI 1871696096
$251,104.28
in general payments reported to CMS, 2019-2025
38 companies · $63K in 2025
The $63K reported for 2025 was more than what 97% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $32K · 2021: $16K · 2022: $35K · 2023: $26K · 2024: $32K · 2025: $63K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $14K · Food and Beverage: $13K · Honoraria: $9,575 · Travel and Lodging: $8,196 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $77,244.00 |
| Consulting Fee | $13,680.00 |
| Food and Beverage | $12,602.31 |
| Honoraria | $9,575.00 |
| Travel and Lodging | $8,196.01 |
| Education | $222.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $47,206.40 | 2019-2023 | Krystexxa |
| Amgen INC. | $39,374.40 | 2019-2025 | Krystexxa, Tavneos, Evenity |
| Astrazeneca Pharmaceuticals Lp | $30,086.84 | 2021-2025 | Saphnelo |
| Janssen Biotech, INC. | $29,086.21 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $23,222.11 | 2019-2025 | Rinvoq, Skyrizi |
| Mallinckrodt Hospital Products INC. | $18,043.36 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $16,135.97 | 2019 | |
| Glaxosmithkline, LLC. | $15,910.60 | 2019-2025 | Benlysta, Nucala |
| Fresenius Kabi USA, LLC | $6,918.35 | 2023-2025 | Idacio |
| Actelion Pharmaceuticals US, INC. | $6,907.25 | 2019-2025 | Opsumit, Uptravi |
| Gilead Sciences, INC. | $5,254.28 | 2019-2020 | |
| Sobi, INC | $2,642.34 | 2019-2025 | |
| Ucb, INC. | $2,410.64 | 2019-2025 | Cimzia, Bimzelx |
| Ani Pharmaceuticals, INC. | $1,309.76 | 2022-2025 | Purified Cortrophin Gel |
| Medexus Pharma, INC. | $1,298.80 | 2019-2021 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $981.21 | 2019-2025 | |
| Pfizer INC. | $725.21 | 2019-2025 | |
| Lilly USA, LLC | $559.38 | 2019-2025 | Taltz, Zepbound |
| Aurinia Pharma U.S., INC. | $441.23 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $432.22 | 2019-2025 | Orencia |
| Genentech USA, INC. | $293.48 | 2019-2025 | Actemra |
| Radius Health, INC. | $280.62 | 2019-2025 | Tymlos |
| Organon LLC | $264.64 | 2021-2025 | Hadlima, Renflexis, Nexplanon |
| Merck Sharp & Dohme LLC | $222.04 | 2023-2025 | Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.43 | 2019-2025 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $156.79 | 2019-2025 | Strensiq |
| Genzyme Corporation | $145.25 | 2021-2025 | |
| Sandoz INC. | $129.91 | 2024-2025 | Hyrimoz |
| Octapharma USA, INC. | $94.46 | 2021-2024 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $82.44 | 2019-2022 | |
| Antares Pharma, INC. | $80.35 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $64.94 | 2019 | |
| Currax Pharmaceuticals LLC | $38.85 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $34.20 | 2021-2022 | |
| Novo Nordisk INC | $27.58 | 2023-2024 | Wegovy |
| Tonix Medicines, INC. | $23.57 | 2025 | Tonmya |
| Celltrion USA INC. | $21.02 | 2023 | Yuflyma |
| Tersera Therapeutics LLC | $20.15 | 2025 | Quzyttir |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.